These agents, including bevacizumab, in combination with chemotherapy, are usually administered to patients with metastatic or late‐stage CRC.[29] However, bevacizumab alone is clinically inefficient, although it is highly effective preclinically in blocking tumor growth and metastasis.[30, 31] Owing to its antiangiogenic potential, the combination of glucagon and chemotherapeutic drugs may produce a synergistic antitumor effect, similar to the combinatory use of bevacizumab and chemotherapeutic drugs in clinical practice. Here, GCG is linked to neoplasm.